Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Somewhat Bullish +42

Bristol Myers Squibb Company $BMY Shares Sold by Mid American Wealth Advisory Group Inc. - MarketBeat

AI-generated analysis

📈 BMY reported quarterly EPS of $2.04, significantly beating the $1.60 consensus estimate, while revenue grew 5.7% year-over-year to $12.97 billion.

💰 The company pays a quarterly dividend of $0.63, representing a 3.8% annualized yield with a payout ratio of 55.51%.

📉 Mid American Wealth Advisory Group cut its BMY position by 27.8%, selling 22,416 shares and retaining approximately $3.35 million worth of stock.

🔬 Bristol Myers Squibb paused enrollment in zola-cel autoimmune cell-therapy trials following the identification of inflammatory safety concerns.

⚠️ Investors face risks from legacy-drug declines, specifically Opdivo, and future patent expiry for Eliquis.

📊 The stock carries a 'Moderate Buy' consensus rating with a price target of $66.06, though analyst targets range widely from $59 to $73.

🚀 BMY is expanding its pipeline into the depression market via a new Phase 2 trial evaluating a therapy in that large potential market.

📈 Analyst sentiment improved recently with upgrades from Sanford Bernstein and JPMorgan Chase raising price targets and ratings.

💼 Institutional ownership remains high at 76.41%, with several funds like Swiss RE initiating new positions valued around $25,000.

📉 Insider selling occurred as SVP Phil Holzer sold 500 shares, reducing his ownership by 2.88% in a transaction worth $33,750.

Bullish Signals
  • Bristol Myers Squibb beat earnings expectations with EPS of $2.04 versus the $1.60 consensus and revenue growth of 5.7% to $12.97 billion.
  • The company offers a defensive income profile with a quarterly dividend of $0.63 yielding 3.8% annually and a low valuation relative to peers.
  • Strong financial health is evidenced by a quick ratio of 1.38, current ratio of 1.53, and a net margin of 18.87%.
  • Analyst sentiment turned more bullish recently with Sanford Bernstein upgrading to 'outperform' and JPMorgan raising its price target to $73.
  • The company is diversifying growth by launching a Phase 2 trial for depression therapy, expanding into a large potential market.
  • Institutional confidence is supported by new positions from funds like Swiss RE and Darwin Wealth Management totaling over $50,000 in the quarter.
Risk Factors
  • Bristol Myers Squibb paused its zola-cel autoimmune cell-therapy trials after safety surveillance identified serious inflammatory side effects.
  • The company faces significant revenue risks from legacy-drug declines, including Opdivo, and the future patent expiry of Eliquis.
  • Mid American Wealth Advisory Group significantly reduced its stake by 27.8%, selling over 22,000 shares in the second quarter.
  • The wider healthcare sector traded lower recently, adding industry-level pressure to BMY's stock performance.
  • Insider selling activity was noted as SVP Phil Holzer sold 500 shares of the company's stock in late August.
Full Analysis
Bristol Myers Squibb (BMY) reported strong quarterly financial results, beating analyst expectations with earnings per share of $2.04 against a consensus of $1.60 and revenue rising 5.7% year-over-year to $12.97 billion. The company maintains a robust balance sheet with a quick ratio of 1.38 and a market capitalization of approximately $136.56 billion, while offering shareholders a quarterly dividend of $0.63 for an annualized yield of 3.8%. Institutional investor activity shows mixed signals regarding the stock's near-term trajectory. Mid American Wealth Advisory Group reduced its position by 27.8%, selling over 22,000 shares, while several other funds including Swiss RE and Darwin Wealth Management initiated new positions valued between $25,000 and $32,000 during the quarter. Analyst consensus remains a 'Moderate Buy' with a price target of $66.06, though individual targets vary from $59 to $73. The company faces specific headwinds including safety concerns that led to a pause in zola-cel autoimmune cell-therapy trials and looming patent expiries for legacy drugs like Eliquis and Opdivo. Conversely, the stock is supported by strong margins, low valuation metrics relative to peers, and positive analyst sentiment following recent upgrades from Sanford Bernstein and JPMorgan Chase. Bristol Myers Squibb is expanding its pipeline into new therapeutic areas, such as a Phase 2 trial for depression therapy, aiming to offset declines in older medicines. While insider selling occurred with SVP Phil Holzer reducing his holdings, the broader institutional ownership stands at 76.41%, indicating continued significant interest from major investors despite sector-wide pressure.